{"pmid":32437478,"title":"Harnessing the natural anti-glycan immune response to limit the transmission of enveloped viruses such as SARS-CoV-2.","text":["Harnessing the natural anti-glycan immune response to limit the transmission of enveloped viruses such as SARS-CoV-2.","PLoS Pathog","Breiman, Adrien","Ruven-Clouet, Nathalie","Le Pendu, Jacques","32437478"],"journal":"PLoS Pathog","authors":["Breiman, Adrien","Ruven-Clouet, Nathalie","Le Pendu, Jacques"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32437478","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1371/journal.ppat.1008556","e_drugs":["Polysaccharides"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1667521393846124544,"score":9.490897,"similar":[{"pmid":32366695,"pmcid":"PMC7199903","title":"Site-specific glycan analysis of the SARS-CoV-2 spike.","text":["Site-specific glycan analysis of the SARS-CoV-2 spike.","The emergence of the betacoronavirus, SARS-CoV-2, the causative agent of COVID-19, represents a significant threat to global human health. Vaccine development is focused on the principal target of the humoral immune response, the spike (S) glycoprotein, which mediates cell entry and membrane fusion. SARS-CoV-2 S gene encodes 22 N-linked glycan sequons per protomer, which likely play a role in protein folding and immune evasion. Here, using a site-specific mass spectrometric approach, we reveal the glycan structures on a recombinant SARS-CoV-2 S immunogen. This analysis enables mapping of the glycan-processing states across the trimeric viral spike. We show how SARS-CoV-2 S glycans differ from typical host glycan processing, which may have implications in viral pathobiology and vaccine design.","Science","Watanabe, Yasunori","Allen, Joel D","Wrapp, Daniel","McLellan, Jason S","Crispin, Max","32366695"],"abstract":["The emergence of the betacoronavirus, SARS-CoV-2, the causative agent of COVID-19, represents a significant threat to global human health. Vaccine development is focused on the principal target of the humoral immune response, the spike (S) glycoprotein, which mediates cell entry and membrane fusion. SARS-CoV-2 S gene encodes 22 N-linked glycan sequons per protomer, which likely play a role in protein folding and immune evasion. Here, using a site-specific mass spectrometric approach, we reveal the glycan structures on a recombinant SARS-CoV-2 S immunogen. This analysis enables mapping of the glycan-processing states across the trimeric viral spike. We show how SARS-CoV-2 S glycans differ from typical host glycan processing, which may have implications in viral pathobiology and vaccine design."],"journal":"Science","authors":["Watanabe, Yasunori","Allen, Joel D","Wrapp, Daniel","McLellan, Jason S","Crispin, Max"],"date":"2020-05-06T11:00:00Z","year":2020,"_id":"32366695","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1126/science.abb9983","e_drugs":["Polysaccharides"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138496195100672,"score":54.543823},{"pmid":32179788,"pmcid":"PMC7075884","title":"Ginkgolic acid inhibits fusion of enveloped viruses.","text":["Ginkgolic acid inhibits fusion of enveloped viruses.","Ginkgolic acids (GA) are alkylphenol constituents of the leaves and fruits of Ginkgo biloba. GA has shown pleiotropic effects in vitro, including: antitumor effects through inhibition of lipogenesis; decreased expression of invasion associated proteins through AMPK activation; and potential rescue of amyloid-beta (Abeta) induced synaptic impairment. GA was also reported to have activity against Escherichia coli and Staphylococcus aureus. Several mechanisms for this activity have been suggested including: SUMOylation inhibition; blocking formation of the E1-SUMO intermediate; inhibition of fatty acid synthase; non-specific SIRT inhibition; and activation of protein phosphatase type-2C. Here we report that GA inhibits Herpes simplex virus type 1 (HSV-1) by inhibition of both fusion and viral protein synthesis. Additionally, we report that GA inhibits human cytomegalovirus (HCMV) genome replication and Zika virus (ZIKV) infection of normal human astrocytes (NHA). We show a broad spectrum of fusion inhibition by GA of all three classes of fusion proteins including HIV, Ebola virus (EBOV), influenza A virus (IAV) and Epstein Barr virus (EBV). In addition, we show inhibition of a non-enveloped adenovirus. Our experiments suggest that GA inhibits virion entry by blocking the initial fusion event. Data showing inhibition of HSV-1 and CMV replication, when GA is administered post-infection, suggest a possible secondary mechanism targeting protein and DNA synthesis. Thus, in light of the strong effect of GA on viral infection, even after the infection begins, it may potentially be used to treat acute infections (e.g. Coronavirus, EBOV, ZIKV, IAV and measles), and also topically for the successful treatment of active lesions (e.g. HSV-1, HSV-2 and varicella-zoster virus (VZV)).","Sci Rep","Borenstein, Ronen","Hanson, Barbara A","Markosyan, Ruben M","Gallo, Elisa S","Narasipura, Srinivas D","Bhutta, Maimoona","Shechter, Oren","Lurain, Nell S","Cohen, Fredric S","Al-Harthi, Lena","Nicholson, Daniel A","32179788"],"abstract":["Ginkgolic acids (GA) are alkylphenol constituents of the leaves and fruits of Ginkgo biloba. GA has shown pleiotropic effects in vitro, including: antitumor effects through inhibition of lipogenesis; decreased expression of invasion associated proteins through AMPK activation; and potential rescue of amyloid-beta (Abeta) induced synaptic impairment. GA was also reported to have activity against Escherichia coli and Staphylococcus aureus. Several mechanisms for this activity have been suggested including: SUMOylation inhibition; blocking formation of the E1-SUMO intermediate; inhibition of fatty acid synthase; non-specific SIRT inhibition; and activation of protein phosphatase type-2C. Here we report that GA inhibits Herpes simplex virus type 1 (HSV-1) by inhibition of both fusion and viral protein synthesis. Additionally, we report that GA inhibits human cytomegalovirus (HCMV) genome replication and Zika virus (ZIKV) infection of normal human astrocytes (NHA). We show a broad spectrum of fusion inhibition by GA of all three classes of fusion proteins including HIV, Ebola virus (EBOV), influenza A virus (IAV) and Epstein Barr virus (EBV). In addition, we show inhibition of a non-enveloped adenovirus. Our experiments suggest that GA inhibits virion entry by blocking the initial fusion event. Data showing inhibition of HSV-1 and CMV replication, when GA is administered post-infection, suggest a possible secondary mechanism targeting protein and DNA synthesis. Thus, in light of the strong effect of GA on viral infection, even after the infection begins, it may potentially be used to treat acute infections (e.g. Coronavirus, EBOV, ZIKV, IAV and measles), and also topically for the successful treatment of active lesions (e.g. HSV-1, HSV-2 and varicella-zoster virus (VZV))."],"journal":"Sci Rep","authors":["Borenstein, Ronen","Hanson, Barbara A","Markosyan, Ruben M","Gallo, Elisa S","Narasipura, Srinivas D","Bhutta, Maimoona","Shechter, Oren","Lurain, Nell S","Cohen, Fredric S","Al-Harthi, Lena","Nicholson, Daniel A"],"date":"2020-03-18T11:00:00Z","year":2020,"_id":"32179788","source":"PubMed","week":"202012|Mar 16 - Mar 22","doi":"10.1038/s41598-020-61700-0","link_erratum_in":"32372013","locations":["Ginkgolic","Ginkgo","Ginkgolic"],"e_drugs":["ginkgolic acid"],"topics":["Mechanism"],"weight":1,"_version_":1666138490587316224,"score":50.80328},{"pmid":32353870,"title":"The many faces of the anti-COVID immune response.","text":["The many faces of the anti-COVID immune response.","The novel 2019 strain of coronavirus is a source of profound morbidity and mortality worldwide. Compared with recent viral outbreaks, COVID-19 infection has a relatively high mortality rate, the reasons for which are not entirely clear. Furthermore, treatment options for COVID-19 infection are currently limited. In this Perspective, we explore the contributions of the innate and adaptive immune systems to both viral control as well as toxicity during COVID-19 infections and offer suggestions to both understand and therapeutically modulate anti-COVID immunity.","J Exp Med","Vardhana, Santosha A","Wolchok, Jedd D","32353870"],"abstract":["The novel 2019 strain of coronavirus is a source of profound morbidity and mortality worldwide. Compared with recent viral outbreaks, COVID-19 infection has a relatively high mortality rate, the reasons for which are not entirely clear. Furthermore, treatment options for COVID-19 infection are currently limited. In this Perspective, we explore the contributions of the innate and adaptive immune systems to both viral control as well as toxicity during COVID-19 infections and offer suggestions to both understand and therapeutically modulate anti-COVID immunity."],"journal":"J Exp Med","authors":["Vardhana, Santosha A","Wolchok, Jedd D"],"date":"2020-05-01T11:00:00Z","year":2020,"_id":"32353870","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1084/jem.20200678","topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138495617335296,"score":49.321968},{"pmid":32275178,"title":"Harnessing innate immunity to eliminate SARS-CoV-2 and ameliorate COVID-19 disease.","text":["Harnessing innate immunity to eliminate SARS-CoV-2 and ameliorate COVID-19 disease.","Physiol Genomics","Golonka, Rachel M","Saha, Piu","Yeoh, Beng San","Chattopadhyay, Saurabh","Gewirtz, Andrew T","Joe, Bina","Vijay-Kumar, Matam","32275178"],"journal":"Physiol Genomics","authors":["Golonka, Rachel M","Saha, Piu","Yeoh, Beng San","Chattopadhyay, Saurabh","Gewirtz, Andrew T","Joe, Bina","Vijay-Kumar, Matam"],"date":"2020-04-11T11:00:00Z","year":2020,"_id":"32275178","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1152/physiolgenomics.00033.2020","keywords":["deoxyribonuclease i","flagellin","interferon","neutrophil extracellular traps","toll-like receptor 5"],"topics":["Treatment"],"weight":1,"_version_":1666138491652669441,"score":45.10015},{"pmid":32485205,"title":"The endosomal lipid bis(monoacylglycero) phosphate as a potential key player in the mechanism of action of chloroquine against SARS-COV-2 and other enveloped viruses hijacking the endocytic pathway.","text":["The endosomal lipid bis(monoacylglycero) phosphate as a potential key player in the mechanism of action of chloroquine against SARS-COV-2 and other enveloped viruses hijacking the endocytic pathway.","The anti-malarial drug Chloroquine (CQ) and its derivative hydroxychloroquine have shown antiviral activities in vitro against many viruses, including coronaviruses, dengue virus and the biosafety level 4 Nipah and Hendra paramyxoviruses. The in vivo efficacy of CQ in the treatment of COVID-19 is currently a matter of debate. CQ is a lysosomotrophic compound that accumulates in lysosomes, as well as in food vacuoles of Plasmodium falciparum. In the treatment of malaria, CQ impairs the digestion and growth of the parasite by increasing the pH of the food vacuole. Similarly, it is assumed that the antiviral effects of CQ results from the increase of lysosome pH and the inhibition of acidic proteases involved in the maturation of virus fusion protein. CQ has however other effects, among which phospholipidosis, characterized by the accumulation of multivesicular bodies within the cell. The increase in phospholipid species particularly concerns bis(monoacylglycero)phosphate (BMP), a specific lipid of late endosomes involved in vesicular trafficking and pH-dependent vesicle budding. It was shown previously that drugs like progesterone, the cationic amphiphile U18666A and the phospholipase inhibitor methyl arachidonyl fluoro phosphonate (MAFP) induce the accumulation of BMP in THP-1cells and decrease cell infection by human immunodeficiency virus. HIV viral particles were found to be retained into large endosomal-type vesicles, preventing virus spreading. Since BMP was also reported to favour virus entry through hijacking of the endocytic pathway, we propose here that BMP could play a dual role in viral infection, with its antiviral effects triggered by lysosomotropic drugs like CQ.","Biochimie","Carriere, Frederic","Longhi, Sonia","Record, Michel","32485205"],"abstract":["The anti-malarial drug Chloroquine (CQ) and its derivative hydroxychloroquine have shown antiviral activities in vitro against many viruses, including coronaviruses, dengue virus and the biosafety level 4 Nipah and Hendra paramyxoviruses. The in vivo efficacy of CQ in the treatment of COVID-19 is currently a matter of debate. CQ is a lysosomotrophic compound that accumulates in lysosomes, as well as in food vacuoles of Plasmodium falciparum. In the treatment of malaria, CQ impairs the digestion and growth of the parasite by increasing the pH of the food vacuole. Similarly, it is assumed that the antiviral effects of CQ results from the increase of lysosome pH and the inhibition of acidic proteases involved in the maturation of virus fusion protein. CQ has however other effects, among which phospholipidosis, characterized by the accumulation of multivesicular bodies within the cell. The increase in phospholipid species particularly concerns bis(monoacylglycero)phosphate (BMP), a specific lipid of late endosomes involved in vesicular trafficking and pH-dependent vesicle budding. It was shown previously that drugs like progesterone, the cationic amphiphile U18666A and the phospholipase inhibitor methyl arachidonyl fluoro phosphonate (MAFP) induce the accumulation of BMP in THP-1cells and decrease cell infection by human immunodeficiency virus. HIV viral particles were found to be retained into large endosomal-type vesicles, preventing virus spreading. Since BMP was also reported to favour virus entry through hijacking of the endocytic pathway, we propose here that BMP could play a dual role in viral infection, with its antiviral effects triggered by lysosomotropic drugs like CQ."],"journal":"Biochimie","authors":["Carriere, Frederic","Longhi, Sonia","Record, Michel"],"date":"2020-06-03T11:00:00Z","year":2020,"_id":"32485205","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.biochi.2020.05.013","e_drugs":["Hydroxychloroquine","Lipids","bis(monoacylglyceryl)phosphate","methyl arachidonylfluorophosphonate","Progesterone","Chloroquine","Phospholipids"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1668532114933415936,"score":44.00171}]}